“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s244. doi:10.25251/skin.7.supp.244.